Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients

NCT01970033 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT01970033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2012
Completion date
January 31, 2015
Enrollment
450 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes